07/19/2024
3:20 PM | Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/10/2024
7:29 PM | Acrivon Therapeutics (Subject)
Chione Ltd (Filed by)
| Form SC 13G/A | |
07/10/2024
7:34 PM | Acrivon Therapeutics (Subject)
Chione Ltd (Filed by)
| Form SC 13G/A | |
06/24/2024
4:36 PM | Acrivon Therapeutics (Issuer)
Kolchinsky Peter (Reporting)
Kolchinsky Peter (Reporting)
RA Capital Healthcare Fund LP (Reporting)
RA Capital Healthcare Fund LP (Reporting)
RA CAPITAL MANAGEMENT, L.P. (Reporting)
RA CAPITAL MANAGEMENT, L.P. (Reporting)
RA Capital Nexus Fund II, L.P. (Reporting)
Shah Rajeev M. (Reporting)
Shah Rajeev M. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/24/2024
4:26 PM | Acrivon Therapeutics (Issuer)
BAUM CHARLES M (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/24/2024
4:27 PM | Acrivon Therapeutics (Issuer)
DiRocco Derek (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/24/2024
4:27 PM | Acrivon Therapeutics (Issuer)
Shacham Sharon (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
|
06/24/2024
4:28 PM | Acrivon Therapeutics (Issuer)
TOMSICEK MICHAEL JOHN (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/16/2024
5:56 PM | Acrivon Therapeutics (Issuer)
Devroe Eric (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/16/2024
5:58 PM | Acrivon Therapeutics (Issuer)
Gamelin Erick (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/16/2024
6:00 PM | Acrivon Therapeutics (Issuer)
Holm-Jorgensen Rasmus (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/16/2024
6:02 PM | Acrivon Therapeutics (Issuer)
Masson Kristina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/16/2024
6:03 PM | Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/16/2024
6:05 PM | Acrivon Therapeutics (Issuer)
Peterson Katharine (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/16/2024
5:52 PM | Acrivon Therapeutics (Issuer)
Peterson Katharine (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
05/16/2024
5:54 PM | Acrivon Therapeutics (Issuer)
Blume-Jensen Peter (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/14/2024
7:00 AM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/14/2024
6:31 AM | Acrivon Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
04/29/2024
11:15 PM | Acrivon Therapeutics (Filer)
| Form EFFECT | |
04/26/2024
7:30 AM | Acrivon Therapeutics (Filer)
| Form DEF 14A | |
04/26/2024
7:30 AM | Acrivon Therapeutics (Filer)
| Form DEF 14A | |
04/26/2024
7:33 AM | Acrivon Therapeutics (Filer)
Acrivon Therapeutics (Filer)
| Form DEFA14A | |
04/26/2024
7:36 AM | Acrivon Therapeutics (Filer)
Acrivon Therapeutics (Filer)
| Form ARS | |
04/17/2024
3:39 PM | Acrivon Therapeutics (Filer)
| Form S-3
Registration statement under Securities Act of 1933 | |
04/15/2024
7:53 AM | Acrivon Therapeutics (Issuer)
EDELMAN JOSEPH (Reporting)
PERCEPTIVE ADVISORS LLC (Reporting)
PERCEPTIVE LIFE SCIENCES MASTER FUND LTD (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/15/2024
7:21 AM | Acrivon Therapeutics (Subject)
PERCEPTIVE ADVISORS LLC (Filed by)
| Form SC 13G/A | |
04/11/2024
3:16 PM | Acrivon Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SC 13D/A | |
04/09/2024
6:05 AM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/29/2024
8:06 AM | Acrivon Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
03/28/2024
7:00 AM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/28/2024
6:36 AM | Acrivon Therapeutics (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/06/2024
3:32 PM | Acrivon Therapeutics (Issuer)
Palani Santhosh (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/04/2024
7:15 AM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/16/2024
4:13 PM | Acrivon Therapeutics (Issuer)
Masson Kristina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/16/2024
4:14 PM | Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/14/2024
3:57 PM | Acrivon Therapeutics (Subject)
CITADEL ADVISORS LLC (Filed by)
| Form SC 13G/A | |
02/14/2024
3:36 PM | Acrivon Therapeutics (Subject)
PERCEPTIVE ADVISORS LLC (Filed by)
| Form SC 13G/A | |
02/14/2024
8:51 AM | Acrivon Therapeutics (Subject)
Marshall Wace North America L.P. (Filed by)
| Form SC 13G/A | |
02/13/2024
2:40 PM | Acrivon Therapeutics (Subject)
Sands Capital Ventures, LLC (Filed by)
| Form SC 13G/A | |
02/09/2024
3:37 PM | Acrivon Therapeutics (Issuer)
Magovcevic-Liebisch Ivana (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/09/2024
3:34 PM | Acrivon Therapeutics (Issuer)
Magovcevic-Liebisch Ivana (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
Nvidia’s Quiet $1 Trillion Pivot (Ad) Nvidia recently added $277 billion in market cap …
IN ONE DAY. Find out details on these three critical Nvidia partners immediately. |
02/08/2024
7:27 AM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/19/2024
3:24 PM | Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/16/2024
3:45 PM | Acrivon Therapeutics (Issuer)
Cuillerot Jean-Marie (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/12/2024
3:46 PM | Acrivon Therapeutics (Issuer)
Cuillerot Jean-Marie (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
01/08/2024
6:28 AM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/17/2023
11:15 PM | Acrivon Therapeutics (Filer)
| Form EFFECT | |
12/08/2023
3:21 PM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/01/2023
3:35 PM | Acrivon Therapeutics (Filer)
| Form S-3
Registration statement under Securities Act of 1933 | |
11/16/2023
6:41 PM | Acrivon Therapeutics (Issuer)
Blume-Jensen Peter (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/16/2023
6:41 PM | Acrivon Therapeutics (Issuer)
Devroe Eric (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/16/2023
6:41 PM | Acrivon Therapeutics (Issuer)
Gamelin Erick (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/16/2023
6:42 PM | Acrivon Therapeutics (Issuer)
Holm-Jorgensen Rasmus (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/16/2023
6:42 PM | Acrivon Therapeutics (Issuer)
Masson Kristina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/16/2023
6:43 PM | Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/09/2023
8:12 AM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/09/2023
7:02 AM | Acrivon Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
10/19/2023
6:45 PM | Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/28/2023
6:13 PM | Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
09/28/2023
6:17 PM | Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/05/2023
4:23 PM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/23/2023
3:19 PM | Acrivon Therapeutics (Issuer)
Blume-Jensen Peter (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/11/2023
7:25 AM | Acrivon Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
08/11/2023
6:11 AM | Acrivon Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
08/11/2023
6:17 AM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
Free ACRV Stock Alerts